Abstract
BackgroundThe identification of novel fecal biomarkers in inflammatory bowel disease (IBD) is hampered by the complexity of the human fecal proteome. On the other hand, in experimental mouse models there is probably less variation. We investigated the fecal protein content in mice to identify possible biomarkers and pathogenic mechanisms.MethodsFecal samples were collected at onset of inflammation in Galphai2-/- mice, a well-described spontaneous model of chronic colitis, and from healthy littermates. The fecal proteome was analyzed by two-dimensional electrophoresis and quantitative mass spectrometry and results were then validated in a new cohort of mice.ResultsAs a potential top marker of disease, peptidase D was found at a higher ratio in Galphai2-/- mouse feces relative to controls (fold change 27; p = 0.019). Other proteins found to be enriched in Gαi2-/- mice were mainly pancreatic proteases, and proteins from plasma and blood cells. A tendency of increased calprotectin, subunit S100-A8, was also observed (fold change 21; p = 0.058). Proteases are potential activators of inflammation in the gastrointestinal tract through their interaction with the proteinase-activated receptor 2 (PAR2). Accordingly, the level of PAR2 was found to be elevated in both the colon and the pancreas of Galphai2-/- mice at different stages of disease.ConclusionsThese findings identify peptidase D, an ubiquitously expressed intracellular peptidase, as a potential novel marker of colitis. The elevated levels of fecal proteases may be involved in the pathogenesis of colitis and contribute to the clinical phenotype, possibly by activation of intestinal PAR2.
Highlights
Inflammatory bowel disease (IBD), mainly ulcerative colitis (UC) and Crohn’s disease (CD), is a potentially devastating disease affecting individuals of all ages
The fecal proteome was analyzed by two-dimensional electrophoresis and quantitative mass spectrometry and results were validated in a new cohort of mice
The level of proteinase-activated receptor 2 (PAR2) was found to be elevated in both the colon and the pancreas of Galphai2-/- mice at different stages of disease. These findings identify peptidase D, an ubiquitously expressed intracellular peptidase, as a potential novel marker of colitis
Summary
Inflammatory bowel disease (IBD), mainly ulcerative colitis (UC) and Crohn’s disease (CD), is a potentially devastating disease affecting individuals of all ages. The concept of using novel fecal protein markers for, for example, diagnosis, monitoring of disease severity, and drug efficacy is promising as it would be non-invasive and accessible. The variation in food intake and gut microbiota between individuals would be expected to cause a high degree of complexity in the fecal proteome [4]. These concerns may hinder the discovery of new markers, when performed in humans―even though some recent advances have been reported [5]. The identification of novel fecal biomarkers in inflammatory bowel disease (IBD) is hampered by the complexity of the human fecal proteome. We investigated the fecal protein content in mice to identify possible biomarkers and pathogenic mechanisms
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have